Volrustomig
- Generic Name
- Volrustomig
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaBiliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05775159
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05685472
- Locations
- 🇯🇵
Research Site, Kashiwa, Japan
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2
Recruiting
- Conditions
- Endometrial CancerGastric CancerMetastatic Castration-resistant Prostate CancerOvarian CancerColorectal CancerUrothelial CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed/CisplatinDrug: Pemetrexed/CarboplatinDrug: Carboplatin/Paclitaxel
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT04686305
- Locations
- 🇹🇷
Research Site, Bornova-Izmir, Turkey
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 371
- Registration Number
- NCT04612751
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 67
- Registration Number
- NCT04522323
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹ðŸ‡
Research Site, Hat Yai, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath